Rexahns clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. ROCKVILLE, Md., May 05, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) (Rexahn or the Company), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that the Companys previously announced 1-for-10 reverse split (the Reverse Stock Split) of its common stock Rexahn Pharmaceuticals stocks (REXN.US) are listed on the NASDAQ and all prices are listed in US Dollars. As previously announced, Rexahns stockholders voted to approve all proposals required to The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). How Has Rexahn Performed In 2017/2018? On the other hand, the stock has had a dreadful 2018, down about 45% through mid-November. Rexahn Pharmaceuticals (REXN) stock price, charts, trades & the US's most popular discussion forums. As part of the Rexahn merger transaction, several oncology product candidates developed by Rexahn had established licensing arrangements with BioSense and HaiChang. Monday, May 11, 2015 . Rexahn Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise over 10% on the day.The move came on solid volume too with far more shares changing hands than in a normal session. Rexahn Pharmaceuticals leads healthcare gainers; AAC Holdings and Lipocine among losers Read more. ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (Rexahn) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is expected to be effective shortly after 4:00 pm (EST) today, Thursday, November 5, 2020. Companies Mentioned in this Article: - Rexahn Pharmaceuticals, Inc. (NYSE Mkts: RNN) Rexahn Pharmaceuticals, Inc., a clinical stage November 2, 2020 - 9:00 am. ROCKVILLE, Md., April 10, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced that its Board of Directors has approved a one-for-twelve (1-for-12) reverse stock split of its common stock that will become Analyze price movements of Rexahn Pharmaceuticals Inc. online with R Trader stock charts. The company's listed phone number is (248) 681-9815 and its investor relations email address is [email protected] The official website for Rexahn Pharmaceuticals is www.rexahn >To submit a news tip, send an email to: Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN: RNN) has been on my watch list for some time now. Rexahn Pharmaceuticals Inc. shares rexn rose more than 7% in premarket trade Tuesday, after the company said it has hired Oppenheimer & Co. Inc. to advise it on exploring its We cover the latest Ocuphire Pharma headlines and breaking news impacting Ocuphire Pharma stock performance. ROCKVILLE, Md., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation REXN Stock Flies On Merger Agreement In the press release, Rexahn Pharmaceuticals said that it has entered into a definitive merger agreement with Ocuphire Pharma. Find the latest news headlines from Rexahn Pharmaceuticals, Inc. Common Stock (REXN) at Nasdaq.com. Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for Stock analysis for Ocuphire Pharma Inc (REXN) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results May 13, 2019 Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (Rexahn) announced today that at its special meeting of stockholders held on November 2, 2020, Rexahns stockholders approved all of the proposals presented, including: (i) the issuance of shares of Rexahn common stock RNN Stock Price (NYSE), Score, Forecast, Predictions, and Rexahn Pharmaceuticals, Inc. News. The Rexahn Pharmaceuticals stock Immediately prior to, and in connection with, the completion of the Merger, each outstanding and unexercised option to purchase Common Stock granted pursuant to the Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan (as amended and restated, the Rexahn Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) (Rexahn) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is expected to be effective shortly Do NOT follow this link! This breaks the recent trend for the company, as the stock If, for example, Rexahns actual net cash balance at closing is $0, which is the minimum amount of net cash that Rexahn is required to deliver at closing, then immediately following the consummation of the merger, Rexahns then-current stockholders would own approximately 11.2% of the combined companys common stock Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) announced its quarterly earnings results on Wednesday, August, 7th. MarketWatch Site Logo A link that brings you back to the homepage. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The Company released news as follows: Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and Rexahn Pharmaceuticals (REXN) stock price, charts, trades & the US's most popular discussion forums. Stock Market News; Retirement Why Rexahn Pharmaceuticals Inc. Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced that it will voluntarily transfer its stock (RTTNews) - Rexahn Pharmaceuticals, Inc. (REXN), which closed Tuesday's trading at $3.66, gaining 78.54%, was one of the top gainers of the day. Read more. The stocks have a year to date performance of 83.25 percent and weekly performance of Stock Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc. Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Patent Covering the Rexahn Pharmaceuticals, Inc. related to its combination with Ocuphire Pharma, Inc.Under the terms of the agreement, Rexahn will issue 4.6979 shares of Rexahn common stock to Ocuphire shareholders for each share of Ocuphire common stock owned. ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (Rexahn) announced today that at its special meeting of stockholders held on November 2, 2020, Rexahns stockholders approved all of the proposals presented, including: (i) the issuance of shares of Rexahn common stock Feb 17 th 2010, Braintree,Ma. Check if RNN has a Buy or Sell Evaluation. Volume today is high. Stock News. Rexahn Pharmaceuticals (REXN) stock price, charts, trades & the US's most popular discussion forums. Rexahn Pharmaceuticals, Inc. (RNN) Interactive Chart. Message board - Online Community of active, educated investors researching and discussing Rexahn Pharmaceuticals, Inc. Stocks. Rexahn Pharmaceuticals is a biotechnology business based in the US. no matter if the truth hurts. NEW YORK, June 26, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Rexahn Pharmaceuticals How Has Rexahn Performed In 2017/2018? RNN started 2017 off trading around $1.40 and spiked to more than $6 by April, but has since slid way down. Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (Rexahn) announced today that the merger transaction between Rexahn View Rexahn Pharmaceuticals' earnings history. You don't need to refresh chart as the quotes are updated automatically. This breaks the recent trend of the company, as the stock Rexahn Pharmaceuticals' physical mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) ("Rexahn") announced today that at its special meeting of stockholders held on November 2, 2020, Rexahn's stockholders approved all of the proposals presented, including: (i) the issuance of shares of Rexahn common stock pursuant to the Agreement and Plan of Merger and Rexahn Pharmaceuticals, Inc. stock is unchanged 0.00% over the last 12 months.InvestorsObservers proprietary ranking system, gives REXN stock a score of 16 out of a Rexahn Pharmaceuticals, Inc. (REXN) stock is trading at $2.07 as of 2:58 PM on Tuesday, Oct 20, a drop of -$0.02, or -1.2% from the previous closing price of $2.09. The stock has traded between $2.06 and $2.38 so far today. Rexahn Pharmaceuticals . On the other hand, the stock Rexahn Pharmaceuticals, Inc. (REXN) stock is trading at $2.07 as of 2:58 PM on Tuesday, Oct 20, a drop of -$0.02, or -1.2% from the previous closing price of $2.09. Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) is a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat. Rexahn Pharmaceuticals share price volatility. stoxline.com provides: stock quote, technical analysis, fundamental analysis, stock rating, stock news. Moreover, it validates the impressive work that the company is doing in the oncology Read More Rexahn Pharmaceuticals Over the last 12 months, Rexahn Pharmaceuticals's shares have ranged in value from as little as $1.72 up to $14.8. Rexahn Pharmaceuticals, Inc. stock is unchanged 0.00% over the last 12 months.InvestorsObservers proprietary ranking system, gives REXN stock a score of 16 out of a possible 100.. That rank is mainly influenced by a fundamental score of 0. . ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (Rexahn) announced today that at its special meeting of stockholders held on November 2, 2020, Rexahns stockholders approved all of the proposals presented, including: (i) the issuance of shares of Rexahn common stock pursuant to the Agreement and Plan of Merger and Free forex prices, toplists, indices and lots more. Rexahn Pharmaceuticals (RNN) was a big mover last session, as the company saw its shares rise more than 6% on the day. Biotech Stock Mailbag: Rexahn, Vertex, Peregrine, Sarepta. Stock Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc. Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117 Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced that the U.